NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: NASDAQ:NRX
- CUSIP: N/A
- Web: www.nephrogenex.com/
- 50 Day Moving Avg: $0.40
- 200 Day Moving Avg: $1.17
- 52 Week Range: $0.10 - $8.90
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.08
- P/E Growth: 0.0000
- Return on Equity: -211.97%
- Return on Assets: -105.90%
- Average Volume: 288,621 shs.
Frequently Asked Questions for NephroGenex (NASDAQ:NRX)
What is NephroGenex's stock symbol?
NephroGenex trades on the NASDAQ under the ticker symbol "NRX."
How were NephroGenex's earnings last quarter?
NephroGenex Inc (NASDAQ:NRX) issued its earnings results on Wednesday, November, 11th. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.12. View NephroGenex's Earnings History.
Where is NephroGenex's stock going? Where will NephroGenex's stock price be in 2017?
1 brokers have issued 12-month price targets for NephroGenex's stock. Their predictions range from $17.50 to $17.50. On average, they anticipate NephroGenex's share price to reach $17.50 in the next twelve months. View Analyst Ratings for NephroGenex.
Who are some of NephroGenex's key competitors?
Some companies that are related to NephroGenex include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), Health Net (HNT), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Patheon NV (PTHN), Catalent (CTLT), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX), Cotiviti Holdings (COTV) and Enerplus Corp (ERF).
Who are NephroGenex's key executives?
NephroGenex's management team includes the folowing people:
- John P. Hamill CPA, Chief Executive Officer, Chief Financial Officer
How do I buy NephroGenex stock?
Shares of NephroGenex can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NephroGenex's stock price today?
MarketBeat Community Rating for NephroGenex (NASDAQ NRX)MarketBeat's community ratings are surveys of what our community members think about NephroGenex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of NephroGenex stock can currently be purchased for approximately $0.14.
Consensus Ratings for NephroGenex (NASDAQ:NRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$17.50 (12,391.08% upside)|
Analysts' Ratings History for NephroGenex (NASDAQ:NRX)
(Data available from 9/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/29/2017||FBR & Co||Reiterated Rating||Outperform||$17.50||Low|
|4/15/2016||Rodman & Renshaw||Reiterated Rating||Neutral||N/A|
|4/8/2016||HC Wainwright||Downgrade||Buy -> Neutral||N/A|
Earnings History for NephroGenex (NASDAQ:NRX)Earnings History by Quarter for NephroGenex (NASDAQ NRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for NephroGenex (NASDAQ:NRX)
Current Year EPS Consensus Estimate: $-0.3000 EPS
Next Year EPS Consensus Estimate: $-1.7100 EPS
Dividend History for NephroGenex (NASDAQ:NRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for NephroGenex (NASDAQ:NRX)
Latest Headlines for NephroGenex (NASDAQ:NRX)
|Reviewing Mylan N.V. (MYL) & NephroGenex (NRX)|
www.americanbankingnews.com - August 5 at 7:08 AM
|Analyzing NephroGenex (NASDAQ:NRX) & Mylan N.V. (MYL)|
www.americanbankingnews.com - July 28 at 4:13 PM
|Reviewing NephroGenex (NRX) & Allergan PLC. (AGN)|
www.americanbankingnews.com - July 25 at 10:18 PM
|Comparing NephroGenex (NASDAQ:NRX) & Allergan PLC. (AGN)|
www.americanbankingnews.com - July 25 at 4:24 PM
|Reviewing Mylan N.V. (MYL) and NephroGenex (NASDAQ:NRX)|
www.americanbankingnews.com - July 18 at 8:25 PM
|Head-To-Head Survey: NephroGenex (NASDAQ:NRX) vs. Allergan PLC. (AGN)|
www.americanbankingnews.com - July 5 at 12:23 AM
|NephroGenex (NRX) Getting Positive Media Coverage, Report Shows|
www.americanbankingnews.com - April 27 at 5:22 PM
|NephroGenex (NRX) Getting Favorable Media Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 20 at 4:26 PM
|Naturex CEO Interview - FY 2016 Results (Video)|
finance.yahoo.com - March 30 at 7:09 PM
|FBR & Co Reiterates "Outperform" Rating for NephroGenex Inc (NRX)|
www.americanbankingnews.com - March 29 at 5:25 PM
|3 Companies Filed For Chapter 11 Bankruptcy Today|
feeds.benzinga.com - May 2 at 2:37 PM
|NephroGenex Files For Bankruptcy Protection Under Chapter 11|
finance.yahoo.com - May 2 at 9:43 AM
|Research Triangle area's biotech sector in steep bear market|
www.bizjournals.com - April 26 at 3:00 PM
|How NephroGenex went from darling to disaster|
www.bizjournals.com - April 14 at 4:30 PM
|NephroGenex downgraded by H.C. Wainwright|
finance.yahoo.com - April 8 at 7:10 AM
|NATUREX - FY 2015 Results|
finance.yahoo.com - March 31 at 2:46 AM
|NEPHROGENEX, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Costs Associated with Exit or D|
biz.yahoo.com - February 24 at 4:31 PM
|Here's Why NephroGenex Plunged 40% On Wednesday|
feeds.benzinga.com - February 24 at 3:16 PM
|NephroGenex stock tumbles after announcement to halt trial over consideration of reverse merger|
www.bizjournals.com - February 24 at 11:24 AM
|NephroGenex Provides Corporate Update|
finance.yahoo.com - February 24 at 9:20 AM
|Q4 2015 NephroGenex Inc Earnings Release - After Market Close|
biz.yahoo.com - February 24 at 7:07 AM
|NephroGenex to Host Conference Call and Webcast on Fourth Quarter and Full Year 2015 Financial Results on Thursday, February 25, 2016|
finance.yahoo.com - February 16 at 8:00 AM
|NephroGenex to Present at the 18th Annual BIO CEO & Investor Conference - Business Wire (press release)|
www.businesswire.com - January 27 at 1:43 PM
|AMGN Gets FDA Nod, Data Awaits RGLS In Feb, FORWARD Puts ALKS On The Back Foot - Nasdaq|
www.nasdaq.com - January 22 at 8:38 PM
|Pre-Open Stock Movers 01/22: (NRX) (EGHT) (CHK) Higher; (CSII) (LGCY) (DGII) Lower (more...) - StreetInsider.com|
www.streetinsider.com - January 22 at 8:38 PM
|NephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin Phase 3 as Planned|
www.streetinsider.com - January 22 at 8:38 PM
|NephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin ... - StreetInsider.com|
www.streetinsider.com - January 21 at 8:49 PM
|4:11 pm NephroGenex announces independent DSMB recommendation to continue Phase 3 study of oral Pyridorin in diabetic nephropathy without modification|
finance.yahoo.com - January 21 at 4:11 PM
|NEPHROGENEX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - January 7 at 4:03 PM
|NephroGenex to Participate in Two Healthcare Conferences in January|
finance.yahoo.com - January 6 at 8:00 AM
|NephroGenex Announces Formation of Scientific Advisory Board|
finance.yahoo.com - January 5 at 8:00 AM
|Raleigh drug developer sees shares soar on good news from FDA|
www.bizjournals.com - December 14 at 5:40 PM
|Thanks, FDA: NephroGenex Investors Rejoice After New Clearance|
finance.yahoo.com - December 14 at 12:52 PM
|NephroGenex (NRX) Stock Soars After FDA Approves Clinical Trials for Kidney Treatment|
www.thestreet.com - December 14 at 11:29 AM
|NephroGenex Announces FDA Clearance of IND Application for Clinical Study of Intravenous Pyridorin in the Treatment of Acute Kidney Injury|
finance.yahoo.com - December 14 at 8:00 AM
|NEPHROGENEX, INC. Financials|
finance.yahoo.com - December 8 at 1:18 PM
|NEPHROGENEX, INC. Files SEC form 8-K, Financial Statements and Exhibits|
biz.yahoo.com - November 13 at 7:14 AM
NephroGenex (NRX) Chart for Tuesday, September, 19, 2017